Literature DB >> 17825907

Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.

Massimo Breccia1, Maurizio Martelli, Laura Cannella, Eleonora Russo, Erica Finolezzi, Caterina Stefanizzi, Anna Levi, Annamaria Frustaci, Giuliana Alimena.   

Abstract

Philadelphia positive (Ph+) chronic myeloid leukaemia (CML) presenting synchronously or following non-Hodgkin lymphoma (NHL) has only rarely been reported. Herein, we refer on a case of Ph+ CML occurring after a breast cancer and a NHL with multiple relapses. After obtaining complete cytogenetic remission with imatinib, the patient presented a new NHL relapse, that was treated with rituximab concomitantly to imatinib. Therapy was well tolerated and the patient is presently alive in complete remission of either NHL and CML. We also reviewed the literature relating the uncommon association of these two unrelated diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825907     DOI: 10.1016/j.leukres.2007.07.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Chronic myeloid leukemia as a secondary malignancy following treatment of diffuse large B-cell lymphoma.

Authors:  Itır Şirinoğlu Demiriz; Emre Tekgündüz; Sinem Civriz Bozdağ; Fevzi Altuntaş
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

Review 2.  Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.

Authors:  Khadega A Abuelgasim; Hinna Rehan; Maha Alsubaie; Nasser Al Atwi; Mohammed Al Balwi; Saeed Alshieban; Areej Almughairi
Journal:  J Med Case Rep       Date:  2018-03-11

3.  ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.

Authors:  Mariko Yoshimura; Kensuke Kojima; Rika Tomimasu; Noriyasu Fukushima; Shinichiro Hayashi; Eisaburo Sueoka; Shinya Kimura
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.